Today, the methylating triazene derivative TMZ is recommended as first-line therapy in IDH wild-type glioblastoma by the European Association of Neuro-Oncology (EANO) and the Society of Neuro-Oncology [11,12]. This evidence concerns the gene IDH2 and glioblastoma.